Skip to main content

Shire SC Study (A Phase 1/2 randomized, double-blind, placebo-controlled, multicenter, ascending dose, safety and PK/PD study of SHP655 (rADAMTS13) in sickle cell disease at baseline health and during acute vaso-occlusive crisis.)

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Hematology

Awarded By

Takeda Development Center Americas, Inc

Start Date

April 9, 2020

End Date

April 15, 2023
 

Administered By

Medicine, Hematology

Awarded By

Takeda Development Center Americas, Inc

Start Date

April 9, 2020

End Date

April 15, 2023